[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576936":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":37,"centralContacts":42,"locations":48,"responsibleParty":62,"collaborators":29,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":29,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":29,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":29,"overallStatus":83,"whyStopped":29,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A","EXPERIMENTAL","CM313",[13],"Biological: CM313 injection",{"label":15,"type":10,"description":11,"interventionNames":16},"Group B",[13],{"label":18,"type":19,"description":20,"interventionNames":21},"Group C","PLACEBO_COMPARATOR","Placebo",[22],"Drug: Placebo",[24,30,33],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"BIOLOGICAL","CM313 injection","CM313 600mg（4ml）\u002Fvial. Subcutaneous injection 600mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.",[9],null,{"type":25,"name":26,"description":31,"armGroupLabels":32,"otherNames":29},"CM313 600mg（4ml）\u002Fvial. Subcutaneous injection 1200mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.",[15],{"type":34,"name":20,"description":35,"armGroupLabels":36,"otherNames":29},"DRUG","Placebo 4 mL\u002Fvial. Subcutaneous injection 4 or 8 mL. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.",[18],[38],{"name":39,"affiliation":40,"role":41},"Xiaofeng Zeng","Peking Union Medical College Hospital","PRINCIPAL_INVESTIGATOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":29,"email":47},"Qian Jia","CONTACT","028-88610620","qianjia@keymedbio.com",[49],{"facility":40,"status":29,"city":50,"state":51,"zip":29,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Beijing","Beijing Municipality","China","CN",{"type":55,"coordinates":56},"Point",[57,58],116.39723,39.9075,{"lat":58,"lon":57},[61],{"name":39,"role":45,"phone":29,"phoneExt":29,"email":29},{"type":63,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100576936","phase-2-study-of-cm313sc-injection-in-systemic-lupus-erythematosussle-100576936",false,"NCT06791772","Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM313(SC) Injection in Subjects With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n1. Males or females aged 18 to 65 years.\n2. Voluntarily signed the informed consent form (ICF).\n3. Patients were diagnosed with systemic lupus erythematosus(SLE) according to the diagnostic classification criteria of the European League against Rheumatism (EULAR)\u002FAmerican College of Rheumatology (ACR) in 2019.\n4. Systemic Lupus Erythematosus Disease Activity Index - 2000(SLEDAI-2K) score ≥6 during screening, and SLEDAI-2K clinical score (except for low complement and\u002For positive anti-dsDNA antibodies) ≥4 during screening and at baseline.\n5. Positive antinuclear antibody and\u002For anti-dsDNA antibody results defined in accordance with the laboratory reference value range of the Central laboratory during the screening.\n6. ≥1British Isles Lupus Assessment Group-2004 (BILAG-2004) organ system rated as A or ≥ 2 organ system rated as B, and Physician's Global Assessment(PGA) score ≥1.0 during screening.\n7. Maintain a stable standard treatment regimen for at least 30 days prior to initial dosing of the investigational product.\n\nExclusion Criteria:\n\n1. Kidney disease: Severe lupus nephritis within within 8 weeks prior to randomization.\n2. Patients with systemic lupus erythematosus(SLE) or non-SLE related central nervous system disease within 8 weeks prior to randomization.\n3. There were non-SLE inflammatory skin or joint diseases that the investigators thought might be evaluated during the screening period.\n4. History of clinically significant diseases.","ALL","18 Years","65 Years",{"count":75,"type":76},150,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","To evaluate the efficacy and safety of CM313(SC) injection in systemic lupus erythematosus(SLE)",[82],"Systemic Lupus Erythematosus","NOT_YET_RECRUITING","2025-01-19",{"date":86,"type":87},"2025-01-24","ACTUAL",{"date":89,"type":76},"2025-02",{"date":91,"type":76},"2027-02",{"name":5,"class":6},1]